179 related articles for article (PubMed ID: 38402613)
1. Analysis of pre-treatment tumors reveals gatekeepers of response to CAR T cells.
Singh N
Mol Ther; 2024 Mar; 32(3):567-568. PubMed ID: 38402613
[No Abstract] [Full Text] [Related]
2. CAR-T cells for solid tumors.
Nat Biotechnol; 2023 May; 41(5):588. PubMed ID: 37193841
[No Abstract] [Full Text] [Related]
3. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
4. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
5. Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies.
Feucht J; Abou-El-Enein M
Mol Ther; 2020 Oct; 28(10):2108-2110. PubMed ID: 32841587
[No Abstract] [Full Text] [Related]
6. Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors.
DeRenzo C; Gottschalk S
Front Immunol; 2019; 10():218. PubMed ID: 30828333
[TBL] [Abstract][Full Text] [Related]
7. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor Design Today and Tomorrow.
Boucher JC; Davila ML
Cancer J; 2021 Mar-Apr 01; 27(2):92-97. PubMed ID: 33750067
[TBL] [Abstract][Full Text] [Related]
10. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
Yu T; Yu SK; Xiang Y; Lu KH; Sun M
Front Immunol; 2022; 13():936496. PubMed ID: 35903099
[TBL] [Abstract][Full Text] [Related]
11. IFNγR Pathway Mediates CAR T Cell Cytotoxicity Against Solid Tumors.
Cancer Discov; 2022 Jun; 12(6):1408. PubMed ID: 35452074
[TBL] [Abstract][Full Text] [Related]
12. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
13. CAR-T Cell Therapy: Challenges and Optimization.
Luo M; Zhang H; Zhu L; Xu Q; Gao Q
Crit Rev Immunol; 2021; 41(1):77-87. PubMed ID: 33822526
[TBL] [Abstract][Full Text] [Related]
14. CAR T-cell therapy for solid tumours.
The Lancet Oncology
Lancet Oncol; 2021 Jul; 22(7):893. PubMed ID: 34197740
[No Abstract] [Full Text] [Related]
15. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
Liu J; Zhou G; Zhang L; Zhao Q
Front Immunol; 2019; 10():456. PubMed ID: 30941126
[TBL] [Abstract][Full Text] [Related]
16. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
17. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of response and resistance to CAR T cell therapies.
Berger TR; Maus MV
Curr Opin Immunol; 2021 Apr; 69():56-64. PubMed ID: 33752101
[TBL] [Abstract][Full Text] [Related]
19. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".
Zhang Y; Li Y; Cao W; Wang F; Xie X; Li Y; Wang X; Guo R; Jiang Z; Guo R
Front Immunol; 2021; 12():799206. PubMed ID: 34975912
[TBL] [Abstract][Full Text] [Related]
20. How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?
Schoenfeld AJ; O'Cearbhaill RE
Cancer J; 2021 Mar-Apr 01; 27(2):134-142. PubMed ID: 33750073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
